ClinicalTrials.gg
No longer availableNCT03315299Updated Feb 7, 2024

Individual Patient Expanded Access Gilteritinib (ASP2215)

An expanded access record providing ASP2215 in AML, sponsored by Etan Orgel. No longer available at 1 site in United States. Open to female participants aged 12 Years to 15 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Etan Orgel · Expanded access

Study type
Expanded access
Access type
Individual patients
Ages
12 Years to 15 Years
Sex
Female
01

Study summary

The purpose of this study is to provide expanded access to ASP2215 for a single subject with refractory FLT3-mutated AML without access to comparable or alternative therapy.

Read the detailed description

This treatment protocol is being conducted in a single pediatric patient while phase 3 ASP2215 studies are ongoing in adult subjects with FLT3-mutated AML.

The subjects will enter the screening period up to 2 weeks prior to the start of treatment.

The subject will be administered treatment over 28-day cycles.

The subjects will complete visits on cycle 1 days 1, 4, 8, 15; cycle 2 days 1, 15, and day 1 of each cycle thereafter until discontinued from the study for toxicity, disease progression, or lack of continued benefit in the judgement of the investigator.

An end of treatment visit will be performed within 7 days after last dose of the investigation product (ASP2215), or prior to initiation of another anticancer therapy, whichever occurs earlier, followed by a 30-day follow up.

02

Conditions studied

  • AML
03

In context

Lead sponsor

Etan Orgel is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 15 Years
Sexes eligible
Female

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Institutional Review Board-/Independent Ethics Committee-approved written and privacy language as per national regulation (e.g., Health Insurance Portability and Accountability Act authorization for United States sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
  2. Subject has a diagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) or therapy-related AML according to World Health Organization classification [Swerdlow et al., 2008] as determined by pathology review at the treating institution.
  3. Subject has presence of the FLT3 mutation (internal tandem duplication [ITD] and/or tyrosine kinase domain [TKD] [D835/I836] mutation) in bone marrow or peripheral blood as determined by local laboratory.
  4. Subject has or relapsed AML (with or without hematopoietic stem cell transplant []) or AML in complete remission (CR) with minimal residual disease by flow cytometry or genetic testing after induction/consolidation regimen.
  5. In the judgment of the investigator, there is no comparable or satisfactory alternative therapy to treat the subject's AML.
  6. Subject has not received any chemotherapy or agent within at least 5 half-lives after stopping that drug and before starting gilteritinib.
  7. Subject must meet the following criteria as indicated on clinical laboratory tests:

    • Serum (AST) and alanine aminotransferase (ALT) \< 3 x institutional (ULN)
    • Serum total \< 2.5 mg/dL, except for subjects with Gilbert's syndrome
    • Serum potassium and serum magnesium > institutional lower limit of normal (LLN).
  8. Subject is able to tolerate oral administration of study drug.
  9. Subject who has developed overall grades II-IV (GVHD) must satisfy the following criteria:

    • No requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1 week of randomization
    • No escalation of in terms of increase of or addition of new agent / modality in prior 2 weeks (note that increasing calcineurin inhibitors or sirolimus to achieve therapeutic trough levels is allowed).
  10. Female subject must either:

    • Be of nonchildbearing potential:
    • (defined as at least 1 year without any menses) prior to screening, or
    • Documented surgically sterile or status posthysterectomy (at least 1 month prior to screening)
    • Or, if of ,
    • Agree not to try to become pregnant during the study and for 180 days after the final study drug administration
    • And have a negative urine pregnancy test at screening
    • And, if heterosexually active, agree to use consistently 2 forms of effective per locally accepted standards (1 of which must be a barrier method) starting at screening and throughout the study period and for 180 days after the final study drug administration.
  11. Female subject must agree not to breastfeed or donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
  12. Subject agrees not to participate in another interventional study while on treatment.
  13. Subject who has a diagnosis of (HIV) may be enrolled as long as their disease is under control on antiretroviral therapy. Precautions should be taken to modify their highly active antiretroviral therapy (HAART) regimen to minimize drug interactions.

Exclusion criteria

Exclusion Criteria:

Subject will be excluded from participation if any of the following apply:

  1. Subject is eligible for enrollment in another ongoing clinical study of gilteritinib.
  2. Subject has participated in a previous or ongoing open-label, randomized treatment study of gilteritinib.
  3. Subject with Fridericia- interval (QTcF) > 450 ms at screening based on local reading.
  4. Subject with Long QT Syndrome at screening.
  5. Subject was diagnosed as acute promyelocytic leukemia (APL).
  6. Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  7. Subject has coagulation abnormality unless secondary to AML in the opinion of the investigator.
  8. Subject has active or C or an active hepatic disorder.
  9. Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or (NYHA) Class IV heart failure.
  10. Subject requires treatment with concomitant drugs that are strong inducers of .
  11. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-gp with the exception of drugs that are considered absolutely essential for the care of the subject.
  12. Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
  13. Subject has any condition which, in the investigator's opinion, makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • Subject will take ASP2215 by mouth daily for 28 day cycles

    Also known as: gilteritinib

06

Where to request access

1 site
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT03315299
Lead sponsor
Etan Orgel
Responsible party
Etan Orgel (Principal Investigator, Children's Hospital Los Angeles) — Sponsor-investigator
First posted
Oct 20, 2017
Last update
Feb 7, 2024
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion